- Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease
-
Srisuwarn P, Eastell R, Salam S
- KMID: 2561863
- J Bone Metab.
- 2024 Nov;31(4):264-278.
- doi: 10.11005/jbm.24.789
Chronic kidney disease (CKD) often leads to mineral and bone disorders (CKD-MBDs), which are nearly universal in patients undergoing dialysis. CKD-MBD includes abnormal calcium-phosphate metabolism, vascular and soft tissue calcification,... -
- CITED
-
- Close
- SHARE
-
- Close
- Platelet Count Normalization Following Romosozumab Treatment for Osteoporosis in Patient with Immune Thrombocytopenic Purpura: A Case Report and Literature Review
-
Sung K, Ha J
- KMID: 2561869
- J Bone Metab.
- 2024 Nov;31(4):335-339.
- doi: 10.11005/jbm.24.763
Romosozumab, which is approved for the treatment of osteoporosis, has a dual-action mechanism that promotes bone formation and inhibits bone resorption. However, its association with an increased risk of major... -
- CITED
-
- Close
- SHARE
-
- Close
- Discriminatory Accuracy of Fracture Risk Assessment Tool in Asian Populations: A Systematic Review and Meta-Analysis
-
Jha D, Chandran M, Hong N, Rhee Y, Baek S, Ferguson SJ, Helgason B, Praveen AD
- KMID: 2561866
- J Bone Metab.
- 2024 Nov;31(4):296-315.
- doi: 10.11005/jbm.24.781
Background: This review explores the discriminative ability of fracture risk assessment tool (FRAX) in major osteoporotic fracture (MOF) and hip fracture (HF) risk prediction and the densitometric diagnosis of osteoporosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Relationships among Physical Activity Bone Mineral Density and Body Composition in Obese and Athletes
-
Suttho D, Apibantaweesakul S, Soponputthaporn J, Hemapaibun S, Santipongphibool M, Tengcharoenkul C
- KMID: 2561868
- J Bone Metab.
- 2024 Nov;31(4):326-334.
- doi: 10.11005/jbm.24.791
Background: Osteoporosis is a significant global public health issue, increasingly affecting younger individuals and placing substantial economic burdens on society. Risk factors vary, with non-modifiable ones like age and ethnicity,... -
- CITED
-
- Close
- SHARE
-
- Close
- Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia
-
Alnaser RI, Alassaf FA, Abed MN
- KMID: 2561862
- J Bone Metab.
- 2024 Nov;31(4):251-263.
- doi: 10.11005/jbm.24.739
Background: Recent studies have linked sarcopenia development to the hallmarks of diabetes, oxidative stress, and insulin resistance. The anti-oxidant and insulin sensitivityenhancing effects of incretin-based therapies may provide a promising... -
- CITED
-
- Close
- SHARE
-
- Close
- Physical Performance Level and Patient-Reported Outcomes in Female Patients with Distal Radius Fracture
-
Oh BH, Kalantan RK, Kim JK, Shin YH
- KMID: 2561867
- J Bone Metab.
- 2024 Nov;31(4):316-325.
- doi: 10.11005/jbm.24.785
Background: This study aimed to evaluate the influence of physical performance level on patient-reported outcomes after surgery for distal radius fractures (DRF). Methods: We retrospectively reviewed 157 women with DRF who... -
- CITED
-
- Close
- SHARE
-
- Close
- Age- and Sex-Related Volumetric Density Differences in Trabecular and Cortical Bone of the Proximal Femur in Healthy Population
-
Brance ML, Saraví FD, Henríquez MM, Larroudé MS, Jacobo JE, Araujo SA, Longobardi V, Zanchetta MB, Ulla MR, Martos F, Salerni H, Oliveri B, Bonanno MS, Meneses NL, Baclini PD, Ramírez Stieben LA, Gregorio SD, Brun LR
- KMID: 2561864
- J Bone Metab.
- 2024 Nov;31(4):279-289.
- doi: 10.11005/jbm.24.765
Background: There are age- and sex-related increases in the prevalence of osteoporosis. Bone densitometry based on dual energy X-ray absorptiometry (DXA) is the gold standard for the assessment of bone... -
- CITED
-
- Close
- SHARE
-
- Close
- Zoledronate Therapy in Osteogenesis Imperfecta: Perspectives in Indonesia Tertiary Hospital
-
Martanto TW, Japamadisaw A, Nurhayati D, Nelissen RGHH
- KMID: 2561865
- J Bone Metab.
- 2024 Nov;31(4):290-295.
- doi: 10.11005/jbm.24.767
Background: Osteogenesis imperfecta (OI) is a rare disease with an estimated incidence of between 1/25,000 and 1/10,000 globally. The main treatment for OI is the administration of bisphosphonate drugs. Research... -
- CITED
-
- Close
- SHARE
-
- Close
